# Kasvu Therapeutics

> TrkB-targeted neuroplastogens for brain disorders.

## Why it is interesting

Kasvu's lead program offers a differentiated attempt to enhance neuroplasticity without relying on psychedelic mechanisms, but remains preclinical.

## Profile

- **Latest funding:** Series A — €30M (September 24, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** stub
- **Last updated:** 2026-09-25
- **Latest funding investors:** Hadean Ventures, Tesi, Innovestor Life Science Fund, Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments, Helsinki University Funds

## Funding history

- Series A · €30M · September 24, 2026
  Source: https://ddcenter.fi/fddc-joins-kasvu-therapeutics-e30-million-series-a-financing-round/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 25, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/kasvu-therapeutics